troglitazone has been researched along with thiophenes in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nelson, SD | 1 |
| Baradaran, B; Majidinia, M; Rameshknia, V; Samadi, N; Shafiei-Irannejad, V; Targhaze, N; Yousefi, B; Zarghami, N | 1 |
1 review(s) available for troglitazone and thiophenes
| Article | Year |
|---|---|
Structure toxicity relationships--how useful are they in predicting toxicities of new drugs?
Topics: Analgesics; Androgen Antagonists; Anti-Inflammatory Agents, Non-Steroidal; Benzophenones; Bromobenzenes; Chromans; Drug-Related Side Effects and Adverse Reactions; Flutamide; Humans; Hypoglycemic Agents; Indoles; Molecular Structure; Oxindoles; Pharmaceutical Preparations; Quinolones; Structure-Activity Relationship; Thiazoles; Thiazolidinediones; Thiophenes; Troglitazone | 2001 |
1 other study(ies) available for troglitazone and thiophenes
| Article | Year |
|---|---|
Differential effects of peroxisome proliferator-activated receptor agonists on doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cell Survival; Chromans; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Fenofibrate; Gene Expression; Humans; K562 Cells; Oxazoles; Peroxisome Proliferator-Activated Receptors; Rhodamine 123; Signal Transduction; Thiazolidinediones; Thiophenes; Troglitazone | 2015 |